S-Ac7-DOg
S-Ac7-DOG is a cationic lipid with biodegradability, low immunogenicity and high nucleic acid transfection capacity, which is commonly used to construct lipid nanoparticles for nucleic acid molecule delivery. S-Ac7-DOG can bind to mRNA, microRNA and self-amplifying RNA through electrostatic interaction. Lipid nanoparticles formed by S-Ac7-DOG enter cells via an energy-dependent endocytic pathway, release nucleic acid cargos, induce antigen-specific CD8+ T cell responses, promote the generation of precursor memory T cells, and regulate neuroinflammatory pathways. S-Ac7-DOG can be used in the research of retinal diseases, neuroinflammation and cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.69%
- CAS No.: 2796227-17-1
- 화학식: C53H97N3O8S2
- 분자량:968.48
-
보관:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Lipid Compound Library
HY-L043
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Liposome Library
HY-L214
-
Ionizable Lipid Compound Library
HY-L251
Biological Activity
S-Ac7-DOg (5 h; stored at 4 °C)-loaded mRNA and saRNA LNPs exhibit consistent physicochemical properties (size, PDI, zeta potential, encapsulation efficiency) suitable for in vitro retinal delivery[1].
S-Ac7-DOg LNPs (0.5 μg; 24 h) mediate efficient cellular uptake and high transfection efficiency in ARPE-19 and MIO-M1 cells for mRNA delivery, with mRNA cargo inducing more eGFP-positive cells than saRNA cargo[1].
S-Ac7-DOg-based LNP (5-80 nM siRNA; 24 h) efficiently silences luciferase activity in Luc-BV2 mouse microglial cells, with comparable performance to other leading formulations at a 40 nM siRNA dose[2].
S-Ac7-DOg-based LNP (5-80 nM siRNA; 24 h) exhibits no cytotoxicity in BV2 mouse microglial cells at siRNA concentrations ranging from 5 to 80 nM after 24 h incubation[2].
S-Ac7-DOg-based LNP (40 nM miR-124; 24 h) achieves the highest miR-124 transfection efficiency in BV2 mouse microglial cells after 24 h incubation at a 40 nM miRNA dose[2].
S-Ac7-DOg-based LNP (40 nM Cy5-miR-124; 1-6 h) are internalized by BV2 mouse microglial cells via an energy-dependent, cholesterol-requiring endocytic pathway, and successfully escape from endosomes over time[2].
S-Ac7-DOG LNPs (50-200 ng mRNA; 24 h) mediate 10- to 100-fold higher eGFP expression than MC3 LNPs in HEK293T, MC38, and CT26 cells, while maintaining low cytotoxicity[3].
S-Ac7-DOG LNPs (50-200 ng mRNA; 24 h) exhibit significantly higher transfection efficiency than MC3 LNPs in CT26 cells, with no difference in cellular LNP association[3].
S-Ac7-DOG LNPs induce earlier onset of human RBC lysis at acidic pH values relative to MC3 LNPs, indicating enhanced membrane rupture activity at higher endosomal pH[3].
S-Ac7-DOG LNPs undergo more robust disassembly in the presence of anionic DOPS:DOPC liposomes at acidic pH values relative to MC3 LNPs, indicating enhanced membrane interaction capacity[3].
S-Ac7-DOG modified eLNPs can effectively bind mRNA and maintain colloidal stability and mRNA binding ability after storage.[4].
S-Ac7-DOG eLNP+ mRNA showed no detectable cytotoxicity and completely protected the mRNA from RNase degradation; cellular uptake was also higher[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BV2 mouse microglial cells
-
Concentration:5, 10, 20, 40, 80 nM siRNA
-
Incubation Time:24 h
-
Result:Did not reduce BV2 cell viability at any tested siRNA concentration.
Showed no dose-dependent cytotoxicity.
-
Cell Line:BV2 mouse microglial cells
-
Concentration:40 nM miR-124
-
Incubation Time:24 h
-
Result:Resulted in the highest intracellular miR-124 levels.
Achieved significantly elevated miR-124 levels relative to miR-negative control LNP.
-
Cell Line:HEK293T human embryonic kidney cells, MC38 mouse colon cancer cells, CT26 mouse colon cancer cells
-
Concentration:50 ng mRNA; 200 ng mRNA
-
Incubation Time:24 h
-
Result:Induced 10- to 100-fold higher eGFP fluorescence compared to benchmark MC3 LNPs across all three cell lines and both mRNA doses.
Displayed low cytotoxicity relative to other tested lipids.
S-Ac7-DOg (5 μg; intramuscular injection; single administration) achieves higher local miR-124 levels in the muscles of healthy mice than MC3-LNP, and induces lower expression levels of proinflammatory cytokines[2].
S-Ac7-DOG LNPs (5 μg mRNA; intramuscular injection; single administration) mediate sustained, local mRNA expression at the injection site, while reducing off-target liver distribution, resulting in higher muscle-to-systemic bioluminescence ratios and higher spleen-to-liver bioluminescence ratios[3].
S-Ac7-DOG LNPs (5 μg mRNA; intramuscular injection; single administration) exhibit low reactogenicity and unique cell tropism compared with MC3 LNPs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2796227-17-1
-
Appearance Liquid
-
분자량 968.48
-
화학식 C53H97N3O8S2
-
Color Colorless to light yellow
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(OCC(OC(CCCCCCC/C=C\CCCCCCCC)=O)CNC(OCCSSCCOC(NCCN1CCCCCC1)=O)=O)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
DMSO : 100 mg/mL (103.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 50 mg/mL (51.63 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li W, et al. Efficacy versus immunogenicity of LNP-mediated delivery of mRNA and self-amplifying RNA upon intravitreal injection in the mouse eye. J Control Release. 2025;385:114027. [Content Brief]
[2]. Ma Z, et al. Lipid nanoparticle-mediated delivery of microRNA-124 reduces neuroinflammation. Biomaterials. 2026;325:123589. [Content Brief]
[4]. Wang H, et al. Admixing of mRNA with Pre-Formed Lipid Nanoparticles Containing a Slightly-Cationic Ionizable Lipid Allows for Efficient mRNA Transfection In Vitro and In Vivo. Adv Healthc Mater. 2025;14(23):e2501788. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.0325 mL | 5.1627 mL | 10.3255 mL | 25.8136 mL |
| 5 mM | 0.2065 mL | 1.0325 mL | 2.0651 mL | 5.1627 mL | |
| 10 mM | 0.1033 mL | 0.5163 mL | 1.0325 mL | 2.5814 mL | |
| 15 mM | 0.0688 mL | 0.3442 mL | 0.6884 mL | 1.7209 mL | |
| 20 mM | 0.0516 mL | 0.2581 mL | 0.5163 mL | 1.2907 mL | |
| 25 mM | 0.0413 mL | 0.2065 mL | 0.4130 mL | 1.0325 mL | |
| 30 mM | 0.0344 mL | 0.1721 mL | 0.3442 mL | 0.8605 mL | |
| 40 mM | 0.0258 mL | 0.1291 mL | 0.2581 mL | 0.6453 mL | |
| 50 mM | 0.0207 mL | 0.1033 mL | 0.2065 mL | 0.5163 mL | |
| DMSO | 60 mM | 0.0172 mL | 0.0860 mL | 0.1721 mL | 0.4302 mL |
| 80 mM | 0.0129 mL | 0.0645 mL | 0.1291 mL | 0.3227 mL | |
| 100 mM | 0.0103 mL | 0.0516 mL | 0.1033 mL | 0.2581 mL |
S-Ac7-DOg Related Classifications
HY-177531 Related Classifications
Powered by Bioz